🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Oruka Therapeutics, Inc. ORKA R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://orukatx.com
Company Profile ↓
$81.15
+429.35% 1Y
Mkt Cap$5.37B
P/E-39.78
P/B5.22
52W High$113.08
52W Low$14.40
Book Value$18.20
EPS (TTM)$-2.04

Company Overview

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.23.

Growth & Price Performance

Stock Price Performance

1 Year:+429.35%
6 Months:+19.80%
3 Months:-11.95%
1 Month:-9.76%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 68% of range
$14.40 $113.08
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)47.45 · Neutral
Price Performance
1M-9.76%
3M-11.95%
6M+19.80%
1Y+429.35%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 28.2% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-39.78
Industry PE
25.61
Forward P/E
-28.35
PEG Ratio
-
Book Value
$18.20
Price to Book
5.22
P/S
-
EV/EBITDA
-36.16
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-25.79%
ROE
-18.23%
ROA
-12.95%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.46
EPS (TTM)
$-2.04

Balance Sheet & Liquidity

Debt/Equity
0.23
Quick Ratio
38.03
Current Ratio
38.51
Debt
$2.55M
Total Assets
$1.14B
Current Assets
$395.25M
Working Capital
$378.62M

Ownership

Promoter Holding
1.26%
Chg in Prom Hold
-0.00%
FII / Inst Holding
116.60%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$5.37B
Total Revenue (TTM)
$0
EBITDA
$-154.94M
Free Cash Flow
$-65.03M
Operating Cash Flow
$-100.92M
Shares Outstanding
66.21M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ORKA Oruka Therapeutics, Inc. R2KR3KPHARMA 81.15 -39.78 $5.37B 0.00% -25.79% -18.23% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -0--0---0---0---0---0---0---0---0-------
Operating Income -2.82M-3.67M-3.94M-4.71M-4.38M-5.56M-4.47M--2.77M-2.16M-1.66M--1.78M-1.51M-1.25M--1.34M-1.31M-1.99M--4.10M-4.84M-4.72M--3.28M-3.22M-2.55M--1.80M-1.97M-1.94M--2.48M-21.49M-29.45M-25.09M-28.43M-34.10M-36.43M-50.11M
Net Income -2.81M-3.65M-3.89M-4.66M-4.34M-5.52M-4.43M-4.20M-2.73M-2.12M-1.59M-1.49M-1.66M-1.44M-1.16M-1.23M-1.32M-1.30M-1.99M-5.12M-4.10M-4.83M-4.71M-5.68M-3.27M-3.15M-2.33M-1.17M-1.35M-1.48M-1.42M-1.09M-2.01M-22.24M-28.62M-21.00M-24.57M-30.28M-31.82M-41.21M
Diluted EPS ----------------------0.34-0.33--0.23-0.22-0.16--0.09-0.10-0.10--0.14-6.96-1.46-0.40-0.46---
R&D Expense 1.72M2.59M2.91M3.72M3.25M4.51M3.49M-1.72M1.15M740.00K-662.00K440.00K347.00K-365.00K372.00K1.05M-2.88M3.58M3.44M-2.18M1.49M1.02M-390.00K254.00K322.00K-165.00K18.67M25.69M19.93M24.09M28.99M29.14M43.26M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ----------0000000000--
Operating Income -------9.18M-7.36M-4.32M-6.94M-9.69M-11.46M-16.61M-18.71M-8.12M-5.81M-9.77M-19.34M-10.60M-7.30M-88.12M-122.05M
Net Income -511.00K-1.46M-5.24M-13.99M-19.43M-9.14M-8.42M-5.36M-4.32M-6.94M-9.69M-11.45M-16.44M-18.49M-7.93M-5.48M-9.74M-19.32M-9.93M-5.34M-83.72M-105.43M
Diluted EPS ------------------1.39-0.69-0.37-3.87-
R&D Expense ------3.11M2.31M1.09M2.93M5.62M7.06M12.35M14.08M4.24M1.83M4.99M13.83M4.75M1.01M75.06M100.64M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Feb 2024Dec 2024Dec 2025
Total Assets -------8.16M6.50M3.21M17.08M16.13M39.57M24.63M12.37M6.83M8.54M50.43M54.92M43.09M37.86M1.00K396.02M488.62M
Total Equity -115.00K-619.00K-678.00K-5.74M-19.69M-38.18M7.41M6.77M5.73M2.91M15.58M14.74M38.07M22.19M10.28M6.03M7.61M46.52M51.04M41.67M37.02M1.00K382.22M471.93M
Cash & Equivalents ------7.76M7.03M5.94M2.92M16.76M15.35M38.80M7.40M8.70M6.61M8.36M49.07M53.36M42.45M37.43M-61.58M46.94M
Total Liabilities -------1.39M770.00K305.00K1.50M1.39M1.50M2.44M2.09M793.00K926.00K3.91M3.88M1.41M841.00K-13.80M16.69M
Current Liabilities -------1.19M754.00K305.00K1.50M1.39M1.50M2.40M2.07M793.00K926.00K3.50M3.50M1.13M637.00K-13.04M15.37M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.32M-6.96M-4.08M-5.29M----17.47M-8.24M-4.80M-7.72M-18.76M-10.91M-5.01M-57.84M-88.21M
Investing Cash Flow 265.00K2.01M--32.00K---12.93M3.05M-4.00K-19.00K-43.00K-2.00K0-330.13M-96.75M
Financing Cash Flow 7.32M3.87M1.05M19.16M---5.85M3.10M6.56M48.45M23.09M00449.54M170.31M
Capital Expenditure -4.00K-19.00K--32.00K-19.00K-11.00K-12.00K-3.00K-4.00K-4.00K-19.00K-43.00K-2.00K-0-189.00K-209.00K
Free Cash Flow -8.33M-6.98M--5.32M----17.48M-8.25M-4.80M-7.74M-18.80M-10.91M-5.01M-58.03M-88.42M

Ratios (Annual)

Figures in %.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------------
Operating Margin % ----------------------
Net Margin % ----------------------
ROE % 82.6%215.2%91.2%71.1%50.9%-123.3%-124.4%-93.6%-148.6%-44.5%-65.7%-30.1%-74.1%-180.0%-131.5%-72.0%-20.9%-37.9%-23.8%-14.4%-21.9%-22.3%
ROCE % -------131.7%-128.1%-148.6%-44.5%-65.7%-30.1%-74.7%-181.8%-134.6%-76.4%-20.8%-37.6%-25.3%-19.6%-23.0%-25.8%

Shareholding Pattern

Insiders
1.26%
Institutions
116.60%
Public Float
118.09%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 13.68% 9.06M $743.72M
2 Blackrock Inc. 7.54% 4.99M $409.74M
3 Venrock Adviser, LLC 6.27% 4.15M $340.63M
4 Fairmount Funds Management LLC 5.60% 3.71M $304.24M
5 Capital World Investors 5.14% 3.40M $279.31M
6 RTW Investments LP 4.74% 3.14M $257.75M
7 State Street Corporation 4.04% 2.67M $219.49M
8 Vanguard Capital Management LLC 3.57% 2.36M $193.86M
9 Paradigm Biocapital Advisors LP 3.24% 2.14M $176.09M
10 Deep Track Capital, Lp 2.91% 1.93M $158.14M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ORKA

Google News ue, 20 Oct 2026

ORKA 261120 20.00C (ORKA261120C20000) Stock Options Chain | Quotes & News - Moomoo

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXSnlDV0NnRGpHREVTWktHelEzVUkyLUNQLWpxTzE0SDFoV3FtTGdsLU9MZ1VfbFhXVElTYWw5Ty1RLTJuSGpUVmtETjlfS2lyXzlZWkthUnVIVk1xLUM0?oc=5" target="_blank">ORKA 261120 20.00C (ORKA261120C20000) S…

Google News Sun, 18 Oct 2026

Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOUE1WZy13ZVo3Y0laS1dlS1NfYU85cXF5c2Jxb3RTRkhKSUlaTVR2NjhwUFU0YjQtNUw5STNOZ1Vpa3pOLWhnSjloOGZWaGxYNlVpWnNLdElOa3NsakFWQ2ZaMTVWdGltWGtGMzNPVlByaUF6aWFSXzMxc3FZbERYWVJhX2tCMWppb3pLMW…

Google News hu, 24 Sep 2026

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPTWlLYTdjamYxd2FFSVlvcXVJa19WQUwyU1hHX1dOemJYMURnYkhCUXJWUUdjdUJxR05sLWhxUVFCaFJJcUZEM0FDMUlnMXlidzNabFlFMmJPZDc3OGtTT3FCSkNRejB5dVRZNFAtU3VCX292T1JNVjVrekY1X1R2Z00zc3Q0dVRHQ2tFRV…

Google News Fri, 28 Aug 2026

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZ0UxQWFKejFuMWVwYUZqb082RWc3OHh6VEdPR2VsMTdjSm5xeURhbFg0bTd2THZiT0J1WHczdThaeU8yTlpYeFAxRGRfU09heDBLVDlwT0JsTnBmd1I0eXRQV3hiQlNFVDFPdlp1OU9ENjlIUEpZcENvdVFTZXdKcFRPaFZFWlUtYmNUVk…

Google News hu, 02 Jul 2026

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares - Benzinga

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxONjZhR0pDek8wSVJPVUJCWlQ3bUdTeFEyVzFZX2I4eHZucElZMDJaNnFNbl9aRThKNGpNVEM0MFQzTXZYeXkwUGZJckFKZC15MFU3VzlGNHdQVUFoMjdTcVZhU0pPOFlTQTNRMUZOYWVLcDh5MlprMkxYcTNTcS1GVjh6REZ2aHBUQm5fbk…

Google News Sun, 18 Oct 2026

ORKA Nov 2026 95.000 call (ORKA261120C00095000) Interactive Stock Chart - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBMVnJmaHQ0UWhRaEtXVHhFdGQxX2tweTFFTDBuaV9TeFlWTzB5bkdPVVg4VUpKeG4wdmI2ZXBEQTJQYmsyazZuczF3R1NpREJDSVB3Nnk5bVZJdWFncVFCbVR0WUxaWWhuZ2RBa1JB?oc=5" target="_blank">ORKA Nov 2026 95.00…

ORKA — Frequently Asked Questions

What is the current share price of Oruka Therapeutics, Inc. (ORKA)?

As of 2026-10-22 16:30 PDT, Oruka Therapeutics, Inc. (ORKA) trades at $81.15 on NasdaqGM. Its 52-week range is $14.40 to $113.08.

What is the market capitalisation of ORKA?

Oruka Therapeutics, Inc. (ORKA) has a market capitalisation of $5.37B on NasdaqGM.

What is the P/E ratio of ORKA?

ORKA trades at a trailing price-to-earnings (P/E) ratio of -39.78. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.22.

What is the return on equity (ROE) of ORKA?

ORKA has a return on equity (ROE) of -18.23%. Its return on capital employed (ROCE) is -25.79%.

Is ORKA a good stock to buy?

This page provides a data-driven analysis of Oruka Therapeutics, Inc. (ORKA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space